




Autophagy is a catabolic pathway activated by 
cellular stress, such as starvation or pathogen 
infection, followed by engulfment of proteins 
and organelles by double-membrane vesicles, 
called autophagosomes. Autophagy can result 
in cellular adaptation, as well as cell survival or 
cell death. The ability of autophagy to play a role 
in both survival and cell death is counterintui-
tive. In addition, autophagy demonstrates tumor 
suppressive qualities, whereby deficiency in 
autophagy leads to cellular transformation and 
tumor development [1-3]. Alternatively, cancer 
cells can also exploit the benefits of autophagy 
by inducing cell survival associated with the 
stressful tumor microenvironment [4], as well as 
damage caused by chemo- and radiotherapies 
[5-7]. Therefore, while autophagy demonstrates 
tumor suppressive actions, it also can confer 
oncogenicity associated with drug and radiore-
sistance.  
 
Resistance of cancer cells to treatment can be 
associated with both autophagy and inhibition 
of the more common apoptosis cell death path-
way. Apoptosis resistance in developing novel 
cancer therapies has been a tremendous chal-
lenge with current chemotherapies. However, a 
greater understanding of the interrelationship 
between apoptosis and autophagy is providing 
precedence for developing new drugs, such as 
BH3 mimetics, that can induce autophagy-
associated cell death in apoptotic resistance 
cells. It is well established that suppression of 
apoptosis induces autophagy, while autophagy 
inhibition causes apoptosis [8, 9]. Identifying 
the “toggle switch” or regulatory mechanisms 
involved in the interrelationship between apop-
tosis- and autophagy-associated cell death is 
imperative for creating optimal chemotherapeu-
tics and inhibiting cancer cell growth. Exploiting 
these regulatory mechanisms may provide new 
targets for developing cancer therapeutics.  
 
Throughout this review, we will discuss chemo-
therapies and mechanisms for inducing cell 
death via the autophagy cell death pathway. 
However, it is important to note that while auto-
phagy cell death was previously considered one 
of the main cell death pathways [10], independ-
ent autophagy cell death may only exist in a few 
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exceptional cases, such as Drosophila develop-
ment [11]. Accumulating evidence is challeng-
ing the concept of autophagic cell death in 
mammalian cells [12-14]. This debate provides 
precedence for developing additional experi-
ments to truly dissect whether cell death associ-
ated with autophagy is actually autophagy cell 
death or cell death via a combination of death 
pathways, such as apoptosis, autophagy, and 
necrosis. Furthermore, this examination has led 
to re-evaluating modes of cell death and creat-
ing additional molecular definitions of cell death 
subroutines for greater classification and clarity 
[15].  
 
Bcl-2:Beclin 1 interaction regulates autophagy 
 
The Bcl-2 family of proteins, Bcl-2, Bcl-xL and 
Mcl-1, are well-known anti-apoptotic mediators; 
however, their roles in inhibiting autophagy are 
becoming more understood. The cytoprotective 
function of Bcl-2 proteins stems from their abil-
ity to antagonize Bax and Bak, and thus prevent 
apoptosis. Beclin 1, a Bcl-2 homology 3 (BH3) 
domain only protein [16], is an essential initia-
tor of autophagy. Beclin 1 recruits key autopha-
gic proteins to a pre-autophagosomal structure, 
thereby forming the core complex consisting of 
Beclin 1, Vps34, and Vps15 [17]. In addition, 
Beclin 1 is a key determining factor as to 
whether cells undergo autophagy or apoptosis 
[18]. Beclin 1 has been shown to interact via its 
BH3 domain with anti-apoptotic Bcl-2 family 
members [19]. This interaction prevents Beclin 
1 from assembling the pre-autophagosomal 
structure, thereby inhibiting autophagy [19]. The 
dual role of Bcl-2 and Bcl-xL in inhibiting both 
apoptosis and autophagic-associated cell death 
makes these proteins ideal chemotherapeutic 
targets. BH3 mimetics, such as (-)-gossypol, 
obatoclax and ABT-737, disrupt the Bcl-
2:Beclin1 interaction and currently are undergo-
ing clinical trials [20, 21]. In addition to being 
promising new therapies, BH3 mimetics are 
providing additional insight into the autophagy-
apoptosis regulatory pathways, as discussed 
below [22]. 
 
Beclin 1 and Bcl-2 expression levels regulate 
autophagic-apoptotic switch 
 
The expression levels of Beclin 1 and Bcl-2 are 
key determinants as to whether cells are resis-
tant to apoptosis or autophagy during tumori-
genesis and chemotherapy. Early studies inves-
tigating the role of autophagy during tumori-
genesis, identified Beclin 1 as a tumor suppres-
sor. Initial studies showed Beclin 1 expression 
was lower in cancer cells versus normal epithe-
lial cells [7]. Heterozygous disruption of BECN1 
promotes tumorigenesis [1], while overexpres-
sion inhibits tumorigenesis [23]. Clinical studies 
have demonstrated that BECN1 is lost in 40% to 
75% of breast and ovarian cancers [23]. In addi-
tion, downregulation of BECN1 has been shown 
in many types of cancers and associated with 
poor prognosis [24-29]. Therefore, the reduced 
expression of Beclin 1 reduces autophagic re-
moval of damaged organelles that generate 
reactive oxygen species and genotoxic stress, 
resulting in cellular transformation.  
 
Bcl-2 expression is upregulated in many human 
cancers and mediates the resistance of cancers 
to chemotherapeutic agents and radiotherapy 
[30, 31]. Bcl-2 is overexpressed in 60% of 
breast cancer patients. Furthermore, breast 
cancer patients with a positive Bcl-2 expression 
have shown a poor response to chemotherapy 
compared with those that had less Bcl-2 expres-
sion [32]. Inhibiting Bcl-2 expression has been 
shown to increase the efficacy of drug treat-
ment by inducing apoptosis and autophagy. In 
MCF-7 cells, downregulation of Bcl-2 by RNA 
interference induced cell death 50% above con-
trol, however, apoptosis only accounted for 11% 
of this cell death at 96 hours [33]. It is possible 
that autophagic cell death was responsible for 
the additional cell death not measured by 
TUNEL assay. Furthermore, cell death was en-
hanced by etoposide and doxorubicin treatment 
in MCF-7 human breast cancer cells [33]. It was 
not determined whether this increase was due 
to apoptotic or autophagic cell death. A more 
recent study demonstrated that inhibiting Bcl-2 
in breast cancer cells via siRNA knockdown did 
not induce apoptosis as expected, however in-
duced autophagic cell death [34]. This autopha-
gic cell death was increased by combination 
treatment with doxorubicin, which increased 
expression of Beclin 1 [34]. Therefore, patient 
screening for Bcl-2 expression and Beclin 1 is 
important in determining what type of chemo-
therapy or combination treatment should be 
utilized for treating patients.  
 
Initial discoveries investigating the interaction 
between Bcl-2 and Beclin 1 were carried out 
using overexpression/inhibition studies. HT-29 
colon carcinoma cells, which do not express 
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detectable levels of Bcl-2, were stably trans-
fected with Bcl-2 expression vector. It was found 
that only HT-29 cells stably expressing Bcl-2 
could inhibit starvation-induced autophagy via 
disrupting the Beclin 1/Vps34 complex. Trans-
fecting HeLa cells, an autophagy-competent cell 
line that expresses Bcl-2, with Bcl-2 siRNA in-
creased the level of starvation-induced auto-
phagy [35]. This demonstrated that Bcl-2 exerts 
an inhibitory effect on autophagy (Figure 1).  
 
Cellular localization and binding partners 
 
In addition to Beclin 1 and Bcl-2 expression lev-
els, cellular localization is a determining factor 
regarding the effects of Bcl-2:Beclin 1 interac-
tion on autophagy and apoptosis. Initial studies 
demonstrated that Bcl-2 and Beclin 1 interact at 
the endoplasmic reticulum (ER) and mitochon-
dria [35]. However, it appears that only Bcl-
2:Beclin 1 localization to the ER results in inhibi-
tion of autophagy. Interestingly, a recent study 
[36] demonstrated that NAF-1 (nutrient-
deprivation autophagy factor-1) binds Bcl-2 at 
the ER, independent of a BH3 domain, and is 
required for Bcl-2 to inhibit Beclin 1-mediated 
autophagy. Beclin 1 and Bcl-2 can form com-
plexes with additional autophagy regulatory pro-
teins at different cellular locations. AMBRA1 
(activating molecule in Beclin 1-regulated auto-
phagy) is a key regulator of autophagy and has 
been shown to interact with both Beclin 1 and 
Bcl-2. In response to autophagic stimuli, unc-51
-like kinase 1 (Ulk1) phosphorylates AMBRA1, 
which results in AMBRA1 dissociation from the 
Dynein motor complex [37]. After dissociation, 
AMBRA1 translocates to the ER, binds to Beclin 
1 in the autophagy initiation complex [37], 
which results in the induction of autophagy. 
Alternatively, a recent study demonstrated that 
Bcl-2 localized to the mitochondria can also 
bind AMBRA1, but ER-localized Bcl-2 does not 
[38]. The Bcl-2:AMBRA1 interaction at the mito-
chondria is downregulated during autophagy, as 
well as during apoptosis. Therefore, Bcl-2 can 
regulate Beclin 1-induced autophagy by direct 
binding to Beclin 1, as well as by sequestering 
the activator of Beclin 1 [38].  
 
Proteins capable of disrupting the Bcl-2:Beclin 1 
complex and inducing autophagy are becoming 
more evident. High mobility group box 1 
(HMGB1), a chromatin-associated nuclear pro-
tein and extracellular damage-associated mo-
lecular pattern molecule (DAMP), is a novel Be-
clin 1-binding protein important in sustaining 
autophagy. HMGB1 competes with Bcl-2 for 
interaction with Beclin 1, and orients Beclin 1 to 
autophagosomes [39]. BNIP3 is another protein 
that inhibits the Bcl-2:Beclin 1 complex, con-
versely via binding to Bcl-2. It was reported that 
via its BH3 domain, BNIP3 is capable of binding 
to Bcl-2, thereby disrupting the interaction be-
tween Bcl-2 and Beclin 1, and inducing auto-
phagy [40]. Therefore, competitive proteins, 
such as HMGB1 and BNIP3, demonstrate an-
other mechanism for inducing autophagy by 




As discussed previously, the cellular localization 
and complex formation of Beclin 1 and its regu-
latory proteins is important for determining 
whether cells undergo apoptosis or autophagy. 
This cellular location and complex formation is 
regulated by phosphorylation of key kinases. 
The dissociation of Bcl-2:Beclin 1 complex can 
occur by phosphorylation of Bcl-2 by stress-
activated c-Jun N-terminal protein kinase 1 
(JNK1) [41]. Furthermore, only the ER-enriched 
pool of Bcl-2 is subjected to regulation of Beclin 
1 binding by JNK1-mediated phosphorylation 
[41], another indication that regulatory mecha-
nisms occur at particular subcellular locations. 
Figure 1. Bcl-2 can inhibit both autophagy- and apop-
tosis-associated cell death. Bcl-2 binds to Bak/Bax, 
therefore preventing apoptosis. Bcl-2 binds to Beclin 
1, preventing assembly of the pre-autophagosomal 
structure, which results in inhibition of autophagy.  
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Once Bcl-2 is phosphorylated and dissociates 
from Beclin 1, autophagy can occur [41]. Upon 
continued JNK pathway activation and Bcl-2 
phosphorylation, the cells will eventually un-
dergo apoptosis via caspase 3 activation [41]. 
Death-associated protein kinase (DAPK) is also 
involved in regulating the Bcl-2:Beclin 1 com-
plex. DAPK phosphorylates a threonine within 
the BH3 domain of Beclin 1, which induces dis-
sociation and allows autophagy to proceed [42].  
 
Apoptosis-induced cleavage of autophagy pro-
teins 
 
Cleavage of key autophagy-related proteins, 
such as Beclin 1 and ATG5, is another regula-
tory mechanism involved in disrupting the Bcl-
2:Beclin 1 complex. Beclin 1 is a key inducer of 
autophagy, but can also be cleaved by caspase 
8 during chemotherapy-induced apoptosis [43]. 
Once Beclin 1 is cleaved, it remains cytosolic 
and cannot induce either autophagy or apop-
tosis, therefore, rendering the protein non-
functioning. Cells expressing a Beclin 1 mutant 
are incapable of being cleaved and less sensi-
tive to chemotherapy in vivo [43]. Therefore, 
chemotherapy-associated cleavage of Beclin 1 
would ultimately disrupt the Bcl-2:Beclin1 com-
plex, and allow cells to undergo apoptosis upon 
treatment. Another study demonstrated, that 
following cleavage of Beclin 1, the C-terminus of 
cleaved Beclin (Beclin 1-C) can acquire a new 
apoptosis-promoting function by translocating 
from the cytosol to the mitochondria, inducing 
apoptosis in response to interleukin-3 depriva-
tion [44]. Furthermore, using a cell free system, 
isolated mitochondria were able to release pro-
apoptotic factors when combined with recombi-
nant Beclin 1-C protein [44]. Therefore, Beclin 1 
can be involved in both autophagy and apop-
tosis depending upon the presence of the full-
length or cleaved form.  
 
ATG5 plays an essential role in inducing auto-
phagy by forming the pre-autophagosome struc-
ture. In addition to regulating autophagy, ATG5 
also functions as a pro-apoptotic protein. Upon 
apoptotic stimuli, calpain, a calcium-dependent 
protease, cleaves ATG5 producing a fragment 
(tATG5) which contains the amino-terminal por-
tion of ATG5 [45]. tATG5 then translocates to 
the mitochondria, triggers cytochrome c release 
and caspase activation [45]. Overexpression of 
Bcl-2 abrogated the effect of tATG5 on cell 
death. Furthermore, tATG5 can disrupt the anti-
apoptotic Bcl-xL-Bax complex by binding to Bcl-
xL which allows the Bax-Bax complex to form, 
inducing apoptosis [45].  
 
BH3 mimetics: exploiting the interaction be-
tween Bcl-2 and Beclin1 and identifying new 
regulatory pathways 
 
This review has discussed many mechanisms 
that regulate the Bcl-2:Beclin 1 complex, includ-
ing Beclin 1 and Bcl-2 expression levels, cellular 
localization, and phosphorylation. BH3 mimetics 
are chemotherapies that bind to Bcl-2 and dis-
rupt the Bcl-2:Beclin 1 complex and induce 
autophagy-associated cell death. In addition to 
demonstrating promise as therapy in clinical 
trials, BH3 mimetics have provided beneficial 
insight into the regulation of the Bcl-2:Beclin 1 
interaction as well as identifying additional path-
ways that are involved in autophagic cell death. 
 
Recent studies from our lab compared treat-
ment with the natural BH3-mimetic, (-)-gossypol 
in treating apoptosis-resistant prostate cancer 
cells with high levels of Bcl-2 versus prostate 
cancer cells with low Bcl-2 expression [46]. (-)-
Gossypol induces similar levels of total cell 
death in both prostate cancer cell lines, how-
ever, the mode of cell death depends upon the 
expression of the Bcl-2 family of proteins [20]. 
In prostate cancer cells with low Bcl-2 expres-
sion, more than 80 percent of cells died via 
apoptotic cell death. Conversely, in prostate 
cancer cells with high Bcl-2 expression, more 
than 60 percent died via induction of the auto-
phagy pathway. This death can be blocked by 
the apoptosis inhibitor Z-VAD in low Bcl-2 ex-
pressing cells and the autophagy inhibitor 3-MA 
or Atg5/Beclin 1 siRNAs in high Bcl-2 expressing 
cells. Thus, the level of Bcl-2 determines which 
type of cell death will be dominant in prostate 
cancer cells after treatment with the Bcl-2 in-
hibitor (-)-gossypol. Furthermore, overexpressing 
Bcl-2 decreased the level of (-)-gossypol-induced 
autophagy, possibly due to the stoichiometric 
abundance of Bcl-2 sequestering Beclin 1 and 
inhibiting autophagy induction [46]. Similar re-
sults were also observed with other BH3-
mimetics, ABT-236 and ABT-737 ([47] and Lian 
and Marquez, manuscript in preparation), indi-
cating that this phenomenon is not compound 
specific. These data suggests that Bcl-2 expres-
sion levels may be a key marker in determining 
whether to utilize BH3 mimetics for chemother-
apy when treating patients.  
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Our research also demonstrated that the BH3-
mimetic (-)-gossypol induces autophagy via 
blocking Bcl-2:Beclin 1 interaction at the ER 
[46]. Upon overexpression of Bcl-2, the complex 
of Bcl-2:Beclin 1 on ER membranes is inter-
rupted by (-)-gossypol prior to the complex of Bcl
-2:Bak/Bax on mitochondria [46]. After treat-
ment with (-)-gossypol, Beclin 1 is liberated from 
Bcl-2 in conjunction with transcriptional upregu-
lation [46]. Together, these events trigger the 
autophagic cascade. Therefore, autophagic cell 
death via (-)-gossypol is Beclin 1-dependent 
[20]. Our data are consistent with that of the 
BH3 mimetic, ABT-737, which also induces 
autophagy by disrupting the Bcl-2:Beclin 1 com-
plex formed at the ER and not mitochondria 
[47]. In addition, our lab has also found that (-)-
gossypol can induce JNK signaling and subse-
quent phosphorylation of Bcl-2, disrupting the 
Bcl-2:Beclin 1 complex (Lian and Marquez, 
manuscript in preparation). 
 
As previously discussed, BH3 mimetics induce 
autophagy by disrupting the Bcl-2:Beclin 1 in-
hibitory complex. A recent compelling study has 
demonstrated that BH3 mimetics, ABT-737 and 
HA14-1, also stimulate other pro-autophagic 
pathways and hence activate the nutrient sen-
sors Sirtuin 1 and AMPK, inhibit mTOR, deplete 
cytoplasmic p53, and trigger the IKK Kinase 
[22]. Activation of autophagy was independent 
of reduced oxidative phosphorylation or reduced 
cellular ATP concentrations. Furthermore, induc-
tion of autophagy by ATBT-737 and HA14-1 was 
completely inhibited by knockdown of Beclin 1 
or Vps34. This suggests that BH3 mimetics can 
act across multiple pathways, eliciting a coordi-
nated effort to maximally induce autophagy. In 
addition, disrupting the Bcl-2:Beclin 1 complex, 
elicits a signaling response that induces multi-
ple signals activating autophagy (Figure 2).  
 
Conclusions and future directions 
 
As this review outlines, multiple mechanisms 
regulate the autophagy- inhibiting Bcl-2:Beclin 1 
complex. The expression levels of Bcl-2 and 
Beclin 1 have demonstrated the importance of 
the affinity for each component in maintaining 
or disrupting this inhibitory complex. The discov-
ery of binding partners that alter the affinity of 
Bcl-2:Beclin 1 for one another, are also becom-
Figure 2. BH3 mimetics (i.e. (-)-Gossypol, ABT-236, ABT-737, HA14-1) bind Bcl-2 and prevent Bcl-2 inhibition of auto-
phagy- and apoptosis-associated cell death. BH3 mimetics can also induce autophagy by activating JNK, Sirtuin 1, 
AMPK, IKK Kinase as well as inhibiting mTOR and depleting cytoplasmic p53.  
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ing more evident. Cellular location, whereby the 
complex is formed at the ER or mitochondria, 
are also important contributing factors as to 
whether this complex affects autophagy. More 
drug treatment research studies are demon-
strating that overriding and disrupting the Bcl-
2:Beclin 1 complex occurs by phosphorylation of 
key kinases, especially JNK phosphorylation of 
Bcl-2. Developing combination therapies be-
tween BH3 mimetics and JNK activators will 
provide a greater “double-hit” effect in disrupt-
ing the Bcl-2:Beclin 1 complex, eventually lead-
ing cancer cells to autophagic/apoptotic cell 
death. Identifying the major mechanisms that 
maintain/disrupt this complex will allow us to 
develop additional drug treatments that can 
target this complex from many approaches en-
suring a greater therapeutic outcome.  
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